N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 54,252 shares at $25.02 ($1.4M) on 2023-11-07, disclosed to the SEC on 2023-11-09.
Open-market sale of $1.4M CERE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.02 | 27,076 | $677K | 49.9% |
| 2 | $25.02 | 27,076 | $677K | 49.9% |
| 3 | $25.16 | 100 | $3K | 0.2% |
| Total | $25.02 avg | 54,252 | $1.4M | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |